



## **AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA481)**

**NICE GUIDANCE ISSUED OCTOBER 2017**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

### **Final Appraisal Recommendation**

**Tacrolimus (Advagraf<sup>®</sup>)**

**Re-submission by:  
Astellas Pharma UK Ltd.**

**Advice No: 0811 – June 2011**

#### **Recommendation of AWMSG**

Tacrolimus (Advagraf<sup>®</sup>) is recommended as an option for restricted use within NHS Wales for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients.

Tacrolimus (Advagraf<sup>®</sup>) is not recommended for use within NHS Wales for the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

Tacrolimus (Advagraf<sup>®</sup>) should be prescribed by brand name to reduce the risk of medication errors.

AWMSG is of the opinion that tacrolimus (Advagraf<sup>®</sup>) may be suitable for shared care for the above indication.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – Advice no. 0811  
Tacrolimus (Advagraf<sup>®</sup>) June 2011 v1.3

**Additional notes:**

The company submission provided evidence of the clinical and cost effectiveness of tacrolimus (Advagraf<sup>®</sup>) within a restricted population of patients within the licensed indication. The submission excluded the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 820), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – Advice no. 0811  
Tacrolimus (Advagraf<sup>®</sup>) June 2011 v1.3